Trials / Recruiting
RecruitingNCT07207707
A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies
A Phase 1a, Open-label, Multicenter, Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of KQB548 in Participants With Advanced Solid Malignancies With a KRAS G12D Mutation
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- Sponsor
- Kumquat Biosciences Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this trial is to learn if KQB548 works to treat patients with advanced solid malignancies with a KRAS G12D mutation. It will also learn about the safety of KQB548. The main questions it aims to answer are: * What is the safe dose of KQB548? * Does KQB548 decrease the size of the tumor? * What happens to KQB548 in the body?
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KQB548 | Oral KQB548 |
Timeline
- Start date
- 2025-09-16
- Primary completion
- 2026-09-01
- Completion
- 2027-03-01
- First posted
- 2025-10-06
- Last updated
- 2026-03-13
Locations
12 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07207707. Inclusion in this directory is not an endorsement.